Molecular monitoring of Tunisian patients with chronic myeloid leukemia

##plugins.themes.academic_pro.article.sidebar##

Published May 14, 2018
Download
pdf
Vol. 95 No. 12 (2017): Issue Dec 2017

##plugins.themes.academic_pro.article.main##

Samia Menif
Yosra Ben Youssef
Hatem Bellaaj
Raihane Ben Lakhal
Adnen Laatiri

Abstract

Background: bcr-abl fusion gene is the hallmark of chronic myeloid leukemia(CML) .RQ-PCR provides an accurate measure of the total leukemia cell mass and the degree to which bcr-abl transcripts are reduced by therapy correlates with progression free survival.
Aim:here we report molecular assessment of residual disease in CML Tunisian  patients
Methods:Between june 2003 and December 2014 we measured bcr-abl mRNA levels in peripheral blood from all Tunisian patientsby quantitative real time polymerase chain reaction (RQ-PCR)
Results:A total of708 patients with a mean age of 42 years were included in this study. based on European Leukemia Net 201380% of the patients achieved an optimal response  20 % were in treatment failure.38 % of the patients achieved RM4which corresponds to a bcr-abl/abl ratio <0.01%,13% of the patients achieved RM4.5corresponding to bcr-abl/abl ratio of 0.0032%.
Conclusion:CML patients had a good response to tyrosine kinase inhibitors treatment. RQ-PCR is helpful in detecting any residual disease and determining the depth of the treatment response.

Keywords:

LMC Bcr-abl imatinib

##plugins.themes.academic_pro.article.details##

References

  1. Verschraegeg CF, Kantarjian HM, Hirsh-ginsbergC,et al .The breakpoint cluster region site in patients with Philadelphia chromosome positive chronic myeloid leukemia. Clinical laboratory,and prognostic correlations. Cancer.1995;76(6):992-997
  2. Kantarjian H,o'brien,jabbour S&al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy:a single institution historical experience.2Blood.2012;119:1981-1987
  3. KantarjianHm,tlpaz M,O'Briens,et al.Survival benefit with imatinibmesylate versus interferon alpha based regimens in newly diagnosed chronic phase chronic myeloid leukemia.Blood.2006;108:1835-40
  4. BaccaraniM,Deininger MW,Rosti G&al .European leukemia Net recommandations for the management of chronic myeloid leukemia: Blood.2013; 122:872-884
  5. Hoffman VS, Baccarani M, Hasford J & al .The EUTOS population -based registry: incidence and clinical characteristics of 2904 CML patients in 20 european countries. Leukemia.2015;29:1336-43 .
  6. Hoglund M,Sandin F,Simonsson B.Epidemiology of chronic myeloid leukemia: an update .Ann. Hematol.2015 ;94supl.2:S241-7
  7. Mendizalbal AM,Younes N,Levine PH: Geographic and income variations in age at diagnosis and incidence of chronic myeloid leukemia.2015 Int .JHematol;27:33-7
  8. Mc Nally RJ, Rowland D, Roman E, et al. Age and sex distributions of hematological malignancies in the UK. Hematol.Oncol.1997; 15 :173-89
  9. Bonner Mr, Williams BA, Rusieki ja et al .Occupational exposure to terbufos and the incidence of cancer in the agricultural health study .cancercauses and control.2010;21 :871-7.
  10. Jabbour E, KantarjianH&al . Chronic myeloid leukemia:2014update on diagnosis, monitoring, and management. Am JHematol.2014;89(5):547-556
  11. Iqbal Z, Manzoor F, Khan M, et al .Frequency of bcr-abl fusion oncogene splice variants associated with chronic myeloid leukemia. .J cancer therapy.2011; 2 :176-180
  12. Prejzner W, Relationship of the BCR gene breakpoint and the type of bcr-abl transcript to clinical course, prognostic indexes, and survival in patients with chronic myeloid leukemia. med monit.2002; 8:BR191-BR197
  13. Hanfstein B,Shlyakhto V,Lauseker M et al :velocity of early bcr-abl transcript elimination as an optimal predictor of outcome in chronic myeloid leukemia patients in chronic phase on treatment with imatinib.Leukemia.2014:548-552.
  14. Deninger M., S.G.O'Brien, Guillot F. et al.International randomized study of interferon vs STI 571(IRIS) 8 year followup: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib. Blood .2009; vol.114,abstract 1126
  15. Ribeiro BF, Miranda EC, Albuquerque DM,&al: Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experience. Clinics.2015; (70):8:550
  16. Mahon FX ,Rea D,Guillot J:discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years :the prospective multicenter stop imatinib (STIM) trial .Lancet oncol. 2010;11:1029-1035
  17. SoveriniS ,Hochhaus A ,Nicolini&al :bcrabl kinase domain mutations analysis in chronic myeloid patients treated with tyrosine kinase inhibitors.Recommandations from an expert panel on behalf of European leukemia net .Blood.2012; 118:1208-15
  18. Frankfurt O,Licht JD.Ponatinib a step forward in overcoming resistance in chronic myeloid leukemia.Clin Cancer research.2013;Nov:1:19(21)5828-34